New CFO Arnd Christ to take up position at MediGene in April

Monday, 19. April 2010 08:30
MediGene AG / New CFO Arnd Christ to take up position at MediGene in April processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.

Martinsried/Munich, April 19, 2010. The biotech company MediGene AG (Frankfurt,
Prime Standard, TecDAX) today announces that the Company's new Chief Financial
Officer Arnd Christ, whose appointment was announced in March, will succeed Dr.
Thomas Klaue on April 19, 2010, and Dr. Klaue has therefore resigned with
immediate effect. The appointment of Mr Christ was scheduled for May 11, 2010,
and the change has become possible earlier because he has been able to terminate
his previous employment as Chief Financial Officer at NovImmune AG in mid-April.

Prof. Dr. Ernst-Ludwig Winnacker, Chairman of the Supervisory Board of MediGene
AG, commented: "We are delighted to welcome Arnd Christ to MediGene as a
respected financial professional with many years of experience in the
biotechnology industry. His appointment successfully concludes the re-alignment
of MediGene's Executive Board with the company's strategic refocusing which
began in 2009. We remain confident in our ongoing drug development programs
which are progressing according to schedule, and we would like to invite our
shareholders to get a first-hand update of the company's progress at the
upcoming annual shareholders meeting."



This press release contains forward-looking statements representing the opinion
of MediGene as of the date of this release. The actual results achieved by
MediGene may differ significantly from the forward-looking statements made
herein. MediGene is not bound to update any of these forward-looking statements.
MediGene is a registered trademark of MediGene. This trademark may be owned or
licensed in select locations only.

- ends -



MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG, TecDax)
biotechnology company located in Martinsried/Munich, Germany, with subsidiaries
in Oxford, UK and San Diego, USA. MediGene is the first German biotech company
to have drugs on the market which are distributed by partner companies. It has
several drug candidates in clinical development and possesses innovative
platform technologies. MediGene focuses on clinical research and development of
novel drugs with focus on oncology.


Contact MediGene AG

Email: investor@medigene.com
Fax: ++49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: ++49 - 89 - 85 65 - 3324
Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946



[HUG#1405017]



--- End of Message ---

MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany

WKN: 502090;ISIN: DE0005020903;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Related Links: Medigene AG
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.